

Breast Cancer

An Observational Study of Kadcyla Safety in Breast Cancer

Trial Status
Completed

Trial Runs In
1 Countries

Trial Identifier
NCT02305641 ML29629

The source of the below information is the publicly available website ClinicalTrials.gov. It has been summarised and edited into simpler language.

Trial Summary:

This is a phase IV, prospective, multicenter, non-interventional study (regulatory post-marketing surveillance) in approximately 500 patients who are to receive Kadcyla (trastuzumab emtansine). Patients administered Kadcyla infusion at physician's discretion will be registered for this surveillance in Korea. Patients will be asked to provide informed consent; data will be collected by electronic Case Report Forms for approximately 8 years.

Hoffmann-La Roche
Sponsor

N/A
Phase

NCT02305641 ML29629
Trial Identifiers

Eligibility Criteria:

Gender
All

Age
≥ 18 Years

Healthy Volunteers
No
